Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors

Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: Shear, proliferation, and the IL-2 receptor

“…For sample D, the difference in proliferation between the cultures was less pronounced, so the agitation was further increased to 300 rpm. Variation in proliferation characteristics between cells from different blood samples has been previously demonstrated and is not unexpected (Knazek et al, 1990;Levine et al, 1998;Robinet et al, 1998). This difference in shear sensitivity between samples C and D may have also been related to the difference in the length of time that the two cultures were allowed to expand following stimulation before they were inoculated into the bioreactors.…”

A flow perfusion bioreactor with controlled mechanical stimulation: Application in cartilage tissue engineering and beyond

“…Hollow iber bioreactors (HFBs) showed success in increasing human tumor-in iltrating lymphocyte cell density from initial 0.35-10 ´ 10 8 to 1.5-5.4 ´ 10 10 total cells in 14-32 days period with 91% cell viability, decreasing expansion time by 80% [52]. Even low distribution is obtained within each iber [53] and extra-capillary low is supplied by shell ports.…”

“…Even low distribution is obtained within each iber [53] and extra-capillary low is supplied by shell ports. A cell-suspension medium is passed through either the extra-or intra-capillary space to provide nutrients with cells seeded inside [54,55], or outside of the ibers [52,56]. HFBs have been successfully used [57][58][59][60][61], and in most experiments, 330 μm, 0.2 μm pore, and 150 μm wall thickness polypropylene hollow ibers are arranged along the axis of high-purity glass tubing, and were held in place with silicon rubber [54][55][56][57][58].…”

Freezing Characteristics of Genetically Modified Lymphocytes for the Treatment of MPS II

“…Ex vivo expanded lymphocytes (mixed populations or specific subpopulations) have been used to treat cancer and acquired im munodeficiency syndrome (AIDS) (15)(16)(17)25,26,30,39,44). Genetically modified lymphocytes have been used to correct severe combined immune deficiency due to adenosine deaminase deficiency (ADA) (3).…”